《Table 1Registry data regarding clinical effects of P2Y12 inhibitors in East Asian patients.a》

  提示：宽带有限、当前游客访问压缩模式

本系列图表出处文件名：随高清版一同展现

《2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI》

1. 获取 高清版本忘记账户？点击这里登录

1. 下载图表忘记账户？点击这里登录

aACS，acute coronary syndrome；AMI，acute myocardial infarction；BARC，bleeding academic research consortium；BleeMACS，bleeding complications in a multicenter international registry of patients discharged after an Acute Coronary Syndrome；CI，confidence inter

In addition to the analysis from randomized clinical trials，several registries have suggested the controversial results in clinical efficacy and safety of ticagrelor for East Asian patients with ACS（Table 1）.In the KAMIR-NIH registry[21]（the Korean prospective observational cohort；n=9355），no significant difference in ischemic events at 12 months was observed between the ticagrelor vs.clopidogrel group（2.1%vs.2.1%，P=0.447）after propensity score matching（572 pairs）.However，the incidence of BARC major bleeding（type 2，3 or 5）was higher in ticagrelor than in clopidogrel（8.0%vs.3.1%，P<0.001）.Taiwan Health Insurance Research Database[22]（27，339 AMI patients）was retrospectively analyzed and showed the different result:the ischemic event rate was 22%lower in the ticagrelor group than in the clopidogrel group（10.6%vs.16.2%；HR，0.779；95%CI:0.684 to 0.887）with the similar risk of major bleeding between the groups（3.2%vs.4.1%；HR，0.731；95%CI:0.522 to 1.026）.There would be concerns regarding reliability in terms with the quality of the registry data.